Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells

The PAX3-FOXO1 fusion gene functions as a transactivator and increases expression of many cancer-related genes. These lead to metastases and other unfavorable outcomes for alveolar rhabdomyosarcoma (ARMS) patients. In order to target ARMS with the PAX3-FOXO1 transactivator, we developed an Oncolytic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Hideki, Sato-Dahlman, Mizuho, Hajeri, Praveensingh, Jacobsen, Kari, Koodie, Lisa, Yanagiba, Chikako, Shanley, Ryan, Yamamoto, Masato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749408/
https://www.ncbi.nlm.nih.gov/pubmed/33338875
http://dx.doi.org/10.1016/j.tranon.2020.100997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749408/
https://www.ncbi.nlm.nih.gov/pubmed/33338875
http://dx.doi.org/10.1016/j.tranon.2020.100997

Ejemplares similares